Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.

Publisher: SAGE Publications Country of Publication: England NLM ID: 9501229 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1708-8267 (Electronic) Linking ISSN: 10815589 NLM ISO Abbreviation: J Investig Med Subsets: MEDLINE

Publication: 2023-: [Thousand Oaks] : SAGE Publications
Original Publication: Thorofare, NJ : Slack, c1994-

Diagnostic Techniques and Procedures* ; Ethnicity*; Biomarkers/*blood ; Diabetes Mellitus, Type 2/*blood ; Diabetes Mellitus, Type 2/*diagnosis ; Liver Cirrhosis/*diagnosis ; Non-alcoholic Fatty Liver Disease/*diagnosis; Cohort Studies ; Female ; Humans ; Inflammation/blood ; Inflammation/diagnosis ; Liver Cirrhosis/blood ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease/blood

Fibromax is a diagnostic tool composed of the combination of 4 non-invasive biomarker panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and NashTest-2) and fibrosis (FibroTest). The purpose of this study was to assess the performance of these biomarker panels in patients with type 2 diabetes mellitus (T2DM). All patients underwent routine labs, a 75 g oral glucose tolerance test, a liver proton magnetic resonance spectroscopy ( ¹ H-MRS) to measure intrahepatic triglyceride content, and a percutaneous liver biopsy to establish the diagnosis of non-alcoholic steatohepatitis (NASH) and to grade and stage the disease in those patients with non-alcoholic fatty liver disease (NAFLD) by ¹ H-MRS. For determination of the scores, plasma samples were blindly provided to establish the SteatoTest, ActiTest, NashTest-2 and FibroTest scores. A total of 220 patients with T2DM were included in this study. When the ability of the SteatoTest to identify patients with T2DM with NAFLD by ¹ H-MRS was assessed, the overall performance expressed as the area under the receiver operating characteristic curve was 0.73 (95% CI 0.65 to 0.81). The performance of the ActiTest and NashTest-2 to diagnose definite NASH among patients with T2DM was 0.70 (95% CI 0.63 to 0.77) and 0.69 (95% CI 0.62 to 0.76), respectively. Regarding the FibroTest score, its performance to identify patients with moderate or advanced fibrosis was 0.67 (95% CI 0.58 to 0.76) and 0.72 (95% CI 0.61 to 0.83), respectively. Non-invasive panels for the diagnosis of steatosis, NASH and/or fibrosis, which were developed and validated in non-diabetic cohorts, underperformed when applied to a large cohort of patients with T2DM. Results from non-diabetic populations should not be extrapolated to patients with T2DM.
Competing Interests: Competing interests: MJM and MPC are employees and stock holders of Quest Diagnostics. JMC is full employee of BioPredictive. TP is the inventor of the tests assessed in the study and founder of BioPredictive. The patents belong to the public organization Asssitance Publique Hôpitaux de Paris.
(© American Federation for Medical Research 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.)

Liver Int. 2018 Oct;38(10):1793-1802. (PMID: 29575516)
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):384-391. (PMID: 29280921)
Hepatology. 2005 Jun;41(6):1313-21. (PMID: 15915461)
Aliment Pharmacol Ther. 2014 Nov;40(9):1081-93. (PMID: 25186086)
BMC Gastroenterol. 2006 Feb 14;6:6. (PMID: 16503961)
Hepatology. 2004 Dec;40(6):1387-95. (PMID: 15565570)
Curr Diab Rep. 2007 Jun;7(3):175-80. (PMID: 17547834)
Diabetes Care. 2011 Mar;34(3):727-9. (PMID: 21278140)
PLoS One. 2012;7(3):e30325. (PMID: 22431959)
Gastroenterology. 2012 Jun;142(7):1592-609. (PMID: 22656328)
Diabetologia. 2016 Jun;59(6):1121-40. (PMID: 27053230)
Hepatology. 2017 Apr;65(4):1132-1144. (PMID: 27981615)
Diabetes Care. 2017 Mar;40(3):419-430. (PMID: 28223446)
Gastroenterology. 2004 Feb;126(2):460-8. (PMID: 14762783)
Eur J Gastroenterol Hepatol. 2018 May;30(5):569-577. (PMID: 29406435)
Clin Gastroenterol Hepatol. 2018 Apr;16(4):558-566.e2. (PMID: 29223443)
Ann Intern Med. 2016 Sep 6;165(5):305-15. (PMID: 27322798)
Liver Int. 2015 Sep;35(9):2139-46. (PMID: 25847730)
Int J Cancer. 2012 Apr 1;130(7):1639-48. (PMID: 21544812)
Clin Gastroenterol Hepatol. 2008 Jul;6(7):828-31. (PMID: 18524692)
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. (PMID: 19523535)
Hepatology. 2013 Apr;57(4):1378-83. (PMID: 23213066)
Diabetes Obes Metab. 2018 Jul;20(7):1702-1709. (PMID: 29527789)
Diabetes Care. 2015 Jul;38(7):1347-55. (PMID: 25887357)
Diabetes. 2003 Oct;52(10):2461-74. (PMID: 14514628)
Diabetes Care. 2007 Nov;30(11):2940-4. (PMID: 17666460)
Diabetes Care. 2007 May;30(5):1212-8. (PMID: 17277038)
Dig Liver Dis. 2012 May;44(5):413-8. (PMID: 22285146)
J Clin Endocrinol Metab. 2009 Oct;94(10):4103-6. (PMID: 19584186)
Hepatology. 2009 Jan;49(1):97-105. (PMID: 19053048)
Am J Gastroenterol. 2013 Dec;108(12):1861-8. (PMID: 24100261)
Hepatology. 2012 Sep;56(3):943-51. (PMID: 22505194)
Am J Gastroenterol. 2006 Mar;101(3):547-55. (PMID: 16542291)
Hepatology. 2016 Jan;63(1):138-47. (PMID: 26171685)
Hepatology. 2011 Jul;54(1):344-53. (PMID: 21520200)
Diabetes Care. 2018 Jan;41(1):187-192. (PMID: 29133343)
Lancet. 2015 Mar 14;385(9972):956-65. (PMID: 25468160)
J Hepatol. 2003 Aug;39(2):222-30. (PMID: 12873819)
Hepatology. 2012 Nov;56(5):1751-9. (PMID: 22707395)

P30 DK079626 United States DK NIDDK NIH HHS

Keywords: diabetes mellitus; fatty liver; hepatitis; insulin

0 (Biomarkers)

Date Created: 20181013 Date Completed: 20200424 Latest Revision: 20220210

20240628

PMC6581087

10.1136/jim-2018-000864

30309884